Advertisement

What Health Technology Assessment System Do we Really Need? A Critical Review of the Current Situation of Health Technology Assessment in Five European Countries

  • Juan E. del Llano-SeñarísEmail author
Chapter
  • 965 Downloads

Abstract

What is health technology assessment (HTA) and why is it important? The original intention of the introduction of HTA in the developed countries was to react to three emerging problems: the strong increase of medical costs, an unexplained variability in clinical practice and the incalculable outcome and long-term effects of many health technologies.

Keywords

European Union Health Technology Assessment National Health System Health Technology Assessment Agency Health Technology Assessment Report 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Rivera López-Tello AJ, García López JL, del Llano Señarís JE. [HTA in five European countries: Learning from one another]. Madrid, Spain: Fundación Gaspar Casal; 2013. Available from: http://www.fgcasal.org/publicaciones/Evaluacion_Tecnologias_Sanitarias_en_cinco_Paises_Europeos.pdf.
  2. 2.
    EUnetHTA [Internet]. 2005 [cited 2014 Mar 31]. Available from: http://www.eunethta.eu/
  3. 3.
    Kristensen FB. EUnetHTA and health policy-making in Europe. Eurohealth (Lond). 2006;12(1): 36-8. Available from: http://www.ncbi.nlm.nih.gov/pubmed/10354763.
  4. 4.
    Instituto de Salud Carlos III. AUnETS [Internet]. 2012 [cited 2014 Mar 31]. Available from: http://aunets.isciii.es/web/guest/
  5. 5.
    Orden SSI/1833/2013, de 2 de octubre, por la que se crea y regula el Consejo de la Red Española de Agencias de Evaluación de Tecnologías Sanitarias y Prestaciones del Sistema Nacional de Salud. [Internet]. Madrid, Spain: Ministerio de Sanidad, Servicios Sociales e Igualdad; 2013 p. 6. Available from: http://www.boe.es/boe/dias/2013/10/11/pdfs/BOE-A-2013-10581.pdf.
  6. 6.
    Proyecto de orden por la que se concreta y actualiza la caretera común básica de servicios asistenciales del sistema nacional de la salud [Internet]. Madrid, Spain: Ministerio de Sanidad, Servicios Sociales e Igualdad; 2012 p. 21. Available from: http://www.msssi.gob.es/normativa/docs/Orcarterabasica.pdf.
  7. 7.
    Ministerio de Sanidad Servicios Sociales e Igualdad. Estadística de Gasto Sanitario Público [Internet]. Madrid, Spain; 2011 p. 18. Available from: http://www.msssi.gob.es/estadEstudios/estadisticas/docs/EGSP2008/egspPrincipalesResultados.pdf.
  8. 8.
    Sacristán JA, Oliva J, Del Llano J, Prieto L, Pinto JL. [What is an efficient health technology in Spain?]. Gac Sanit. 2002;16(4):334-43. Available from: http://linkinghub.elsevier.com/retrieve/pii/S021391110271933X.
  9. 9.
    Sanz-Granda A, Hidalgo A, del Llano JE, Rovira J. Analysis of economic evaluations of pharmacological cancer treatments in Spain between 1990 and 2010. Clin Transl Oncol. 2013;15(1):9-19. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23180344.
  10. 10.
    EUnetHTA. JA1 WP5 methodology guideline - Comparators & Comparisons: Criteria for the choice of the most appropriate comparator(s) [Internet]. 2013 [cited 2014 May 14]. p. 24. Available from: http://5026.fedimbo.belgium.be/sites/5026.fedimbo.belgium.be/files/Choice_of_comparator.pdf.
  11. 11.
    Real Decreto-ley 16/2012, de 20 de abril, de medidas urgentes para garantizar la sostenibilidad del Sistema Nacional de Salud y mejorar la calidad y seguridad de sus prestaciones. [Internet]. Madrid, Spain: Jefatura del Estado; 2012 p. 35. Available from: https://www.boe.es/boe/dias/2012/04/24/pdfs/BOE-A-2012-5403.pdf.
  12. 12.
    Oliva J, Del Llano J, Sacristán JA. [Analysis of economic evaluations of health technologies performed in Spain between 1990 and 2000]. Gac Sanit. 2002;16 Suppl 2:2-11. Available from: http://www.ncbi.nlm.nih.gov/pubmed/15826599.
  13. 13.
    C.F. [The HTA agencies sparsely promote their reports]. Diario Medico. Madrid, Spain; 2014 May 21;9.Google Scholar
  14. 14.
    Drummond M, Neumann P, Jönsson B, Luce B, Schwartz JS, Siebert U, et al. Can we reliably benchmark health technology assessment organizations? Int J Technol Assess. Health Care. 2012;28(2):159-65. Available from: http://www.ncbi.nlm.nih.gov/pubmed/22559758.
  15. 15.
    Sorenson C, Drummond M, Kanavos P. Ensuring value for money in health care - The role of health technology assessment in the European Union. Political Science. Copenhagen, Denmark: WHO Regional Office for Europe on behalf of the European Observatory on Health Systems and Policies; 2008. Available from: http://www.ispor.org/congresses/prague1110/documents/PlenaryII-Role-of-HTA-in-the-EU.pdf.
  16. 16.
    HAS - French National Authority for Health [Internet]. [cited 2014 Mar 31]. Available from: http://www.has-sante.fr/portail/jcms/r_1455134/fr/about-has?portal=r_1455081.
  17. 17.
    IQWiG - Institute for Quality and Efficiency in Health Care [Internet]. [cited 2014 Mar 31]. Available from: https://www.iqwig.de/en/home.2724.html.
  18. 18.
    NICE - National Institute for Health and Care Excellence [Internet]. [cited 2014 Mar 31]. Available from: http://www.nice.org.uk.
  19. 19.
    SBU – Swedish Council on Health Technology Assessment [Internet]. [cited 2014 Mar 31]. Available from: http://www.sbu.se/en/.
  20. 20.
    Danish Centre for Health Technology Assessment. Final Tecnical Report EUnetHTA – European network for Health Technology Assessment [Internet]. Copenhagen, Denmark; 2009. Available from: http://ec.europa.eu/health/ph_systems/docs/eunethta_report_en.pdf.
  21. 21.
    OECD. Health expenditure per capita. Health at a Glance: Europe 2012 [Internet]. OECD Publishing; 2012 [cited 2014 Apr 25]. Available from: http://dx.doi.org/10.1787/9789264183896-52-en.
  22. 22.
    Trio Presidency of the European Union. Notes of the Trio Presidency - Health care across Europe: Striving for added value. Informal Health Council. Aachen, Germany: European Union; 2007. p. 6. Available from: http://www.eu2007.de/en/News/download_docs/April/0419-BSGV/090Triopapier.pdf.
  23. 23.
    Danzon M, Maripuu M. The Tallinn Charter: Health Systems for Health and Wealth. WHO European Ministeral Conference on Health Systems: “Health Systems, Health and Wealth”. Tallinn, Estonia: WHO Regional Office for Europe; 2008. p. 5. Available from: http://www.euro.who.int/_data/assets/pdf_file/0008/88613/E91438.pdf.
  24. 24.
    Buzek J, Györi E. Directive on the application of patients’ rights in cross-border healthcare. Strasbourg, France: European Parliament and Council; 2011. p. 45-65. Available from: http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:L:2011:088:0045:0065:en:PDF.
  25. 25.
    Barroso JM. Implementing Decision providing the rules for the establishment, management and transparent functioning of the Network of national authorities or bodies responsible for health technology assessment. Brussels, Belgium: European Commission; 2013. p. 71-2. Available from: http://ec.europa.eu/health/technology_assessment/docs/impl_dec_hta_network_en.pdf.
  26. 26.
    Porter ME, Olmsted Teisberg E. Redefining health care: Creating value-based competition on results. 1st ed. Boston, MA, USA: Harvard Business Review Press; 2006.Google Scholar
  27. 27.
    Oortwijn W, Broos P, Vondeling H, Banta D, Todorova L. Mapping of health technology assessment in selected countries. Int J Technol Assess Health Care. 2013;29(4):424-34. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24290336.
  28. 28.
    INAHTA-International Network of Agencies for Health Technology Assessment [Internet]. [cited 2014 Apr 14]. Available from: http://www.inahta.org.
  29. 29.
    Value-based health: the new normal in healthcare. The Economist Intelligence Unit. London, Great Britain; 2014;4-10.Google Scholar
  30. 30.
    Paris V, Belloni A. Value in pharmaceutical pricing. OECD Health Working Papers. 2013. Report No.: 63. Available from: http://www.oecd-ilibrary.org/social-issues-migration-health/value-inpharmaceutical-pricing_5k43jc9v6knx-en.
  31. 31.
    Rovira Forns J, Gómez Pajuelo P, del Llano Señarís JE. [Value-based pricing of drugs]. Fundación Gaspar Casal, Editor. Madrid, Spain; 2012. http://www.fgcasal.org/publicaciones/Lilly_FGC-Libro_La_Regulacion_del_precio_medicamentos.pdf.

Copyright information

© Springer International Publishing Switzerland 2015

Authors and Affiliations

  1. 1.Gaspar Casal FoundationMadridSpain
  2. 2.Spanish Association for Healthcare Technology Evaluation (AEETS)MadridSpain

Personalised recommendations